Stephen Smolinski
Corporate Officer/Principal at PRECIGEN, INC.
Profile
Stephen Smolinski is currently the Senior VP & Head of Business Development at Precigen, Inc. He previously worked as the Vice President of Marketing at Savient Pharmaceuticals, Inc. from 2011 to 2013, the VP & Head of North American Rheumatology Business at Genzyme Therapeutics Ltd.
from 2015 to 2017, the Global Head of Immunology Therapeutic Area at Swedish Orphan Biovitrum AB, and the Chief Commercial Officer at Avalo Therapeutics, Inc. He received his undergraduate degree from Oregon State University.
Stephen Smolinski active positions
Companies | Position | Start |
---|---|---|
PRECIGEN, INC. | Corporate Officer/Principal | - |
Former positions of Stephen Smolinski
Companies | Position | End |
---|---|---|
CARTESIAN THERAPEUTICS, INC. | Corporate Officer/Principal | 2020-08-17 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 2016-12-31 |
SAVIENT PHARMACEUTICALS INC | Sales & Marketing | 2013-05-31 |
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Stephen Smolinski
Oregon State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
PRECIGEN, INC. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Selecta Biosciences, Inc.
Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Stephen Smolinski